通过权重基因共同表达网络分析和机器学习来发现莱姆病中枢基因和免疫透的识别
Yan Dong1,2, Meng Liu3, Yanshuang Luo3
1Department of Pain Medicine, The Affiliated Anning First People's Hospital of Kunming University of Science and Technology, Kunming, 650302, Yunnan, China.
European journal of medical research
|September 27, 2025
概括
研究人员通过对外围血液单核细胞 (PBMC) 的生物信息学分析,确定KIAA1199是莱姆病 (LD) 病原发生的一个关键基因. 这一发现为LD的新诊断方法提供了潜力.
科学领域:
- 基因组学就是基因组学.
- 免疫学 免疫学 免疫学
- 生物信息学是一种生物信息学.
背景情况:
- 由Borrelia burgdorferi (Bb) 引起的莱姆病 (LD) 是一种复杂的疾病,具有多种症状.
- 对于LD病原和免疫失调的分子基础还没有完全理解.
- 周围血液单核细胞 (PBMC) 在免疫反应中起着至关重要的作用.
研究的目的:
- 确定与LD相关的PBMC中的最佳特征基因 (OFGs).
- 在LD中分析免疫细胞透模式.
- 开发针对莱姆病的新型诊断策略.
主要方法:
- 对转录基因数据集的综合生物信息学分析 (GSE42606,GSE68765,GSE103481).
- 权重基因共同表达网络分析 (WGCNA) 和机器学习 (SVM-RFE,LASSO,RF) 用于OFG识别.
- 免疫细胞透分析 (CIBERSORT) 和功能丰富 (GSEA,ssGSEA).
主要成果:
- 在LD患者中鉴定了174个差异表达基因 (DEG).
- 通过多种机器学习方法,KIAA1199成为了独特的OFG.
- KIAA1199与免疫路径和诊断潜力有很强的相关性.
结论:
- 综合WGCNA和机器学习从PBMC数据中确定KIAA1199作为LD病变发生的核心基因.
- 使用已识别的基因的预测模型显示出显著的诊断准确性.
- 这项研究为了解宿主免疫反应和开发LD新诊断工具提供了基础.
相关概念视频
Genome-wide Association Studies-GWAS
12.6K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
12.6K
Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121

